CorVel Corporation

NASDAQ:CRVL

Insurance - Brokers

Financial Services
$88.87 -0.12%

-$0.07 today

Market cap
$4.47B
Beta
0.98
P/E (TTM)
26.9
EPS (TTM)
$2.16
52W Low $44.83High $105.51

Volume 0.26M

Average 0.22M

CRVL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CorVel CorporationNASDAQ: CRVL

Research & Development · Q2 FY2027 · quarter ended Sep 2026

Research & development remains negative

Q2 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearMar 2026
$0— YoY
LTMSep 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
0 USD
Year-over-year change
—

Research & Development vs competitors

How CRVL compares with its peers on the latest reported figures

  • CRVL's LTM Sep 2026 research & development of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CRVL, versus a peer median of 0.0%.
CRVL Competitors Peer median
Research & Development for CRVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HQYHealthEquity, Inc.LTM Jul 2026$277.96M +10.7%+10.7%20.4%
CRVLCorVel CorporationLTM Sep 2026$0 ——0.0%
EVHEvolent Health, Inc.LTM Mar 2026$0 ——0.0%
CTEVClaritev CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding CRVL) $0+10.7%+10.7%0.0%

Competitors are the stored peer set for CRVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue646.23M718.56M795.31M895.59M958.53M
Cost of Revenue494.12M560.3M623.62M685.86M725.66M
Gross Profit152.11M158.26M171.69M209.73M232.86M
Gross Margin23.5%22.0%21.6%23.4%24.3%
Research & Development00000
Selling, General & Admin67.6M73.71M76.59M88.9M89.73B
Operating Expenses67.6M73.71M76.59M88.9M89.73M
Depreciation & Amortization23.92M25.12M26.25M29.54M31.76M
EBITDA108.43M109.68M121.35M150.36M174.9M
EBITDA Margin16.8%15.3%15.3%16.8%18.2%
Operating Income84.51M84.55M95.1M120.82M143.13M
Operating Margin13.1%11.8%12.0%13.5%14.9%
Interest Income00000
Interest Expense00000
Other Income / Expenses00000
Income Before Tax84.51M84.55M95.1M120.82M143.13M
Pre-Tax Margin13.1%11.8%12.0%13.5%14.9%
Income Tax Expense18.1M18.19M18.85M25.66M32.79M
Net Income66.41M66.37M76.25M95.17M110.34M
Net Margin10.3%9.2%9.6%10.6%11.5%
EPS (Basic)1.251.281.481.852.15
EPS (Diluted)1.221.261.471.832.14
Weighted Avg Shares53.26M51.98M51.37M51.39M51.28M
Weighted Avg Shares (Diluted)54.38M52.78M52.04M52.04M51.63M

CorVel Corporation

NASDAQ:CRVL

Intrinsic Alpha fair value

Locked

Current Price

$88.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.